Associate Professor DEYAMA, Satoshi
Faculty, Affiliation
Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences
Associate Professor
College and School Educational Field
Laboratory
Laboratory of Molecular Pharmacology
Academic Background
【Academic background(Doctoral/Master's Degree)】
Kyoto University Doctor Graduate School of Pharmaceutical Sciences 200903 Completed
Kyoto University Master Graduate School of Pharmaceutical Sciences 200603 Completed
【Academic background(Bachelor's Degree)】
Kyoto University 200403
【Degree】
Ph.D.
Career
Kanazawa University Institute of Medical, Pharmaceutical and Health Sciences Associate Professor(2021/01/01-)
Kanazawa University Institute of Medical, Pharmaceutical and Health Sciences Assistant Professor(2016/08/01-2020/12/31)
Yale University School of Medicine Department of Psychiatry Postdoc(2014/07/01-2016/07/22)
Hokkaido University Graduate School of Pharmaceutical Sciences Assistant Professor(2012/07/01-2014/06/30)
Hokkaido University Graduate School of Pharmaceutical Sciences Assistant Professor(2012/04/01-2012/06/30)
Ono Pharmaceuticals Co Ltd. Scientist(2009/04/01-2012/03/31)
Year & Month of Birth
Academic Society
Japanese Pharmacological Society
The Pharmaceutical Society of Japan
Japanese Society of Neuropsychopharmacology
Japan Neuroscience Society
Society for Neuroscience
Award
Society for Neuroscience
Society for Neuroscience
○Finalist for the Somerfeld-Ziskind Research Award(2021/05/04)
○JSNP Excellent Presentation Award for CINP 2021 Virtual Congress(2021/03)
○35th JPS Young Researchers Award(2020/03/18)
○Excellent Presentation Award for AsCNP2019(2019/10/13)
○JSNP Excellent Presentation Award for AsCNP2019(2019/10/13)
○JSNP Excellent Presentation Award for AsCNP2019(2019/10/13)
○Outstanding presentation award at the 90th Annual Meeting of the JPS(2017/03/17)
Specialities
Neuropharmacology, Molecular Psychiatry
Speciality Keywords
Psychiatric Disorders, Depression, Obsessive compulsive disorder, Rapid-acting antidepressant, ketamine、resolvins、Resilience
Research Themes
Elucidation of the mechanisms underlying the antidepressant actions of rapid-acting agents Identification of novel therapeutic targets for the treatment of major depressive disorder
Books
Papers
- Overview of the mechanisms underlying the fast antidepressant actions of ketamine Deyama S, Kaneda K Japanese Journal of Clinical Psychopharmacology 26 10 967-972 2023/09/22
- Elucidation of the mechanisms underlying the rapid antidepressant actions of ketamine and search for possible candidates for novel rapid-acting antidepressants Deyama S. Yakugaku Zasshi 143 9 713-720 2023/09/01
- Antidepressant-like effects of tomatidine and tomatine, steroidal alkaloids from unripe tomatoes, via activation of mTORC1 in the medial prefrontal cortex in lipopolysaccharide-induced depression model mice. Deyama S, Sugie R, Tabata M, Kaneda K. Nutr Neurosci in press 2023/09/13
- Varenicline enhances recognition memory via α7 nicotinic acetylcholine receptors in the medial prefrontal cortex in male mice. Esaki H, Deyama S, Izumi S, Katsura A, Nishikawa K, Nishitani N, Kaneda K. Neuropharmacology 239 109672 2023/11/15
- Noradrenergic stimulation of α1 adrenoceptors in the medial prefrontal cortex mediates the acute stress-induced facilitation of seizures in mice. Niitani K, Ito S, Wada S, Izumi S, Nishitani N, Deyama S, Kaneda K. Sci Rep 13 8089 2023/05/19
- Role of 5-HT1A receptors in the basolateral amygdala on 3,4-methylenedioxymethamphetamine-induced prosocial effects in mice. Esaki H, Sasaki Y, Nishitani N, Kamada H, Mukai S, Ohshima Y, Nakada S, Ni X, Deyama S, Kaneda K. Eur J Pharmacol 946 175653 2023/05/05
- Neohesperidin exerts antidepressant-like effect via the mechanistic target of rapamycin complex 1 in the medial prefrontal cortex in male mice Deyama S, Aoki S, Sugie R, Kaneda K. J Pharmacol Sci 156 2 82-85 2024/10
- Role of medial prefrontal cortex voltage-dependent potassium 4.3 channels in nicotine-induced enhancement of object recognition memory in male mice. Esaki H, Izumi S, Nishikawa K, Nagayasu K, Kaneko S, Nishitai N, Deyama S, Kaneda K. Eur J Pharmacol 978 176790 2024/09/05
- Neuron-specific deletion of VEGF or its receptor Flk-1 occludes the antidepressant-like effects of desipramine and fluoxetine in mice. Deyama S, Li XY, Duman RS Neuropsychopharmacol Rep 44 246-249 2024/03
- Social defeat stress enhances the rewarding effects of cocaine through α1A adrenoceptors in the medial prefrontal cortex of mice. Saito A, Murata H, Niitani K, Nagasaki J, Otoda A, Chujo Y, Yanagida J, Nishitani N, Deyama S, Kaneda K. Neuropharmacology 2023/10
- Intranasal administration of resolvin E1 produces antidepressant-like effects via BDNF/VEGF-mTORC1 signaling in the medial prefrontal cortex. 35 Deyama S, Aoki S, Sugie R, Fukuda H, Shuto S, Minami M, Kaneda K Neurotherapeutics 20 484-501 2023/03
- Resolvin E1 as a potential lead for the treatment of depression Deyama S, Minami M, Kaneda K. in press 2023/02/20
- Resolution of depression: Antidepressant actions of resolvins. Deyama S, Kaneda K, Minami M. Neurosci Res in press 2022/10/19
- Role of BDNF and VEGF in the rapid antidepressant effects of ketamine Satoshi Deyama, Katsuyuki Kaneda Japanese Journal of Biological Psychiatry 33 4 178-182 2022/12/25
- Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine Deyama S, Kaneda K Neuropharmacology 224 109335 2023/02
- Nicotine enhances object recognition memory through inhibition of voltage-dependent potassium 7 channels in the medial prefrontal cortex of mice. Esaki H, Izumi S, Fukao A, Nishitani N, Deyama S, Kaneda K J Pharmacol Sci 2021/05
- A spatiotemporal increase of neuronal activity accompanies the motivational effect of wheel running in mice. Zhang T, Nishitani N, Niitani K, Nishida R, Futami Y, Deyama S, Kaneda K. Behav Brain Res 432 113981 2022/08
- IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine. Deyama S, Kondo M, Shimada S, Minami M. Transl Psychiatry 12 178 2022/05/17
- The antidepressant effect of resolvin E1 in repeated prednisolone-induced depression model mice. Aoki S#, Deyama S*, #, Sugie R# (#equally contribution), Ishimura K, Fukuda H, Shuto S, Minami M, Kaneda K*. Behav Brain Res 418 113676 2022/02
- Resolvin E1 attenuates chronic pain-induced depression-like behavior in mice: Possible involvement of chemerin receptor ChemR23. Suzuki H, Otsuka T, Hitora-Imamura N, Ishimura K, Fukuda H, Fujiwara K, Shuto S, Deyama S, Minami M. Biol Pharm Bull 44 10 1548-1550 2021/10
- Resolvin D2 attenuates chronic pain-induced depression-like behavior in mice. Suzuki H, Hitora-Imamura N, Deyama S, Minami M. Neuropsychopharmacol Rep 41 3 426-429 2021/09
- Resolvins as potential candidates for the treatment of major depressive disorder. Deyama S, Minami M, Kaneda K. J Pharmacol Sci 147 1 33-39 2021/09
- Nicotine enhances object recognition memory via stimulating of α4β2 and α7 nicotinic acetylcholine receptors in the medial prefrontal cortex of mice. Esaki H, Izumi S, Fukao A, Ito S, Nishitani N, Deyama S, Kaneda K Biol Pharm Bull 2021/05
- Nicotine enhances firing activity of layer 5 pyramidal neurons in the medial prefrontal cortex through inhibition of Kv7 channels. Izumi S, Domoto M, Esaki H, Sasase H, Nishitani N, Deyama S, Kaneda K. Biol Pharm Bull 44 724-731 2021/05
- Role of BDNF in the pathophysiology and treatment of depression: activity dependent effects distinguish rapid acting antidepressants. Duman RS, Deyama S, Fogaça M. Eur J Neurosci 53 1 126-139 2021/01
- Role of 5-HT1A receptor-mediated serotonergic transmission in the medial prefrontal cortex for acute restraint stress-induced augmentation of rewarding memory of cocaine in mice Chu J#, Deyama S#, Li X#(#equally contribution), Motono M, Otoda A, Saito A, Esaki H, Nishitani N, Kaneda K. Neurosci Lett 743 135555 2021/01
- Resolvins as novel targets for rapid-acting antidepressants Deyama S Nihon Yakurigaku Zasshi 155 6 381-385 2020/11
- Neural mechanisms underlying stress-induced enhancement of cocaine craving behaviors Kaneda K, Deyama S, Li X, Zhang T, Sasase H Nihon Yakurigaku Zasshi 155 3 135-139 2020/05
- Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine. Deyama S, Duman RS. Pharmacol Biochem Behav 188 172837 2020/01
- Angiotensin-converting enzyme inhibitors produce rapid antidepressant effects in a bradykinin-dependent manner Deyama S Nihon Yakurigaku Zasshi 155 5 353 2020/05
- Differential sensitivity to detect prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA) in different social approach paradigms in mice. Mukai S, Nakada S, Kamada H, Yaguchi R, Deyama S, Kaneda K. Neuropsychopharmacol Rep 40 297-301 2020/09
- The duration of the antidepressant-like effects of a single infusion of brain-derived neurotrophic factor into the medial prefrontal cortex in mice Deyama S, Kaneda K Behav Brain Res 394 112844 2020/09
- Role of the bed nucleus of the stria terminalis in inflammation-associated anorexia Satoshi Deyama Nihon Yakurigaku Zasshi 155 3 195 2020/05
- Acute restraint stress augments the rewarding memory of cocaine through activation of α1 adrenoceptors in the medial prefrontal cortex of mice. Wada S, Yanagida J, Sasase H, Zhang T, Li X, Kamii H, Domoto M, Deyama S, Hinoi E, Yamanaka A, Nishitani N, Nagayasu K, Kaneko S, Minami M, Kaneda K. Neuropharmacology 166 107968 2020/01
- Neuron-specific deletion of VEGF or its receptor Flk-1 impairs recognition memory. Deyama S, Li XY, Duman RS. Eur Neuropsychopharmacol 31 145-151 2020/02
- Acute cocaine reduces excitatory synaptic transmission in pyramidal neurons of mouse medial prefrontal cortex. Sasase H, Izumi S, Deyama S, Hinoi E, Kaneda K. Biol Pharm Bull 42 1433-1436 2019/05
- Analyses of cocaine rewarding memories by AAV vector-induced introduction of DREADD system Kaneda K, Deyama S, Hinoi E, Yanagida J, Zhang T, Sasase H Nihon Yakurigaku Zasshi 153 5 219-223 2019/05
- Effects of the synthetic cannabinoid 5F-AMB on anxiety and recognition memory in mice. Ito S*, Deyama S* (*equally contribution), Domoto M, Zhang T, Sasase H, Fukao A, Esaki H, Hinoi E, Kaneko S, Kaneda K. Psychopharmacology (Berl) 236 7 2235-2242 2019/07
- Neurotrophic and antidepressant actions of brain-derived neurotrophic factor require vascular endothelial growth factor. Deyama S, Bang E, Kato T, Li X-Y, Duman RS. Biol Psychiatry 86 2 143-152 2019/07
- The synthetic cannabinoid 5F-AMB changes the balance between excitation and inhibition of layer V pyramidal neurons in the mouse medial prefrontal cortex. Domoto M, Sasase H, Wada S, Ito S, Deyama S, Hinoi E, Kaneko S, Kaneda K. Psychopharmacology (Berl) 235 8 2367-2376 2018/08
- Suppressive effects of morphine injected into the ventral bed nucleus of the stria terminalis on the affective, but not sensory, component of pain in rats. Maruyama C*, Deyama S* (*equally contribution), Nagano Y, Ide S, Kaneda K, Yoshioka M, Minami M. Eur J Neurosci 47 1 40-47 2018/01
- Activation of GABAergic neurons in the nucleus accumbens mediates the expression of cocaine-associated memory. Zhang T*, Deyama S* (*equally contribution), Domoto M, Wada S, Yanagida J, Sasase H, Hinoi E, Nishitani N, Nagayasu K, Kaneko S, Kaneda K. Biol Pharm Bull 41 7 1084-1088 2018/07
- Resolvin E3 attenuates lipopolysaccharide-induced depression-like behavior in mice. Deyama S, Shimoda K, Ikeda H, Fukuda H, Shuto S, Minami M. J Pharmacol Sci 138 1 86-88 2018/09
- Role of neuronal VEGF signaling in the prefrontal cortex in the rapid antidepressant effects of ketamine. Deyama S, Bang E, Wohleb ES, Li XY, Kato T, Gerhard DM, Dutheil S, Dwyer JM, Taylor SR, Picciotto MR, Duman RS. Am J Psychiatry 176 5 388-400 2019/05
- Glutamatergic neurons in the medial prefrontal cortex mediate the formation and retrieval of cocaine-associated memories in mice Zhang T, Yanagida J, Kamii H, Wada S, Domoto M, Sasase H, Deyama S, Takarada T, Hinoi E, Sakimura K, Yamanaka A, Maejima T, Mieda M, Sakurai T, Nishitani N, Nagayasu K, Kaneko S, Minami M, Kaneda K. Addict Biol 2019/02
- BDNF release and signaling are required for the antidepressant actions of GLYX-13. Kato T, Fogaça MV, Deyama S, Li X-Y, Fukumoto K, Duman RS. Mol Psychiatry 23 2007-2017 2018/10
- Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23. Deyama S, Shimoda K, Suzuki H, Ishikawa Y, Ishimura K, Fukuda H, Hitora-Imamura N, Ide S, Satoh M, Kaneda K, Shuto S, Minami M. Psychopharmacology (Berl) 235 1 329-336 2018/01
- Resolvin D1 and D2 reverse lipopolysaccharide-induced depression-like behaviors through the mTORC1 signaling pathway. Deyama S*, Ishikawa Y* (*equally contribution), Yoshikawa K, Shimoda K, Ide S, Satoh M, Minami M. Int J Neuropsychopharmacol 20 7 575-584 2017/07
- Rapid and sustained antidepressant effects of resolvin D1 and D2 in a chronic unpredictable stress model. Ishikawa Y*, Deyama S* (*equally contribution), Simoda K, Yoshikawa K, Ide S, Satoh M, Minami M. Behav Brain Res 332 233-236 2017/08
- Involvement of the bed nucleus of the stria terminalis in the negative affective component of visceral and somatic pain in rats. Deyama S, Nakagawa T, Kaneko S, Uehara T, Minami M. Behav Brain Res 176 367-371 2007
- Inhibition of glutamatergic transmission by morphine in the basolateral amygdaloid nucleus reduces pain-induced aversion. Deyama S, Yamamoto J, Machida T, Tanimoto S, Nakagawa T, Kaneko S, Satoh M, Minami M. Neurosci Res 59 199-204 2007
- Activation of the β-adrenoceptor-protein kinase A signaling pathway within the ventral bed nucleus of the stria terminalis mediates the negative affective component of pain in rats. Deyama S, Katayama T, Ohno A, Nakagawa T, Kaneko S, Yamaguchi T, Yoshioka M, Minami M. J Neurosci 28 7728-7736 2008
- Role of enhanced noradrenergic transmission within the ventral bed nucleus of the stria terminalis in visceral pain-induced aversion in rats. Deyama S, Katayama T, Kondoh N, Nakagawa T, Kaneko S, Yamaguchi T, Yoshioka M, Minami M. Behav Brain Res 197 279-283 2009
- Roles of β- and α2-adrenoceptors within the central nucleus of the amygdala in the visceral pain-induced aversion in rats. Deyama S, Takishita A, Tanimoto S, Ide S, Nakagawa T, Satoh M, Minami M. J Pharmacol Sci 114 123-126 2010
- Inhibition of noradrenaline release by clonidine in the ventral bed nucleus of the stria terminalis attenuates pain-induced aversion in rats. Deyama S, Ide S, Kondoh N, Yamaguchi T, Yoshioka M, Minami M. Neuropharmacology 61 156-160 2011
- Activation of β-adrenoceptors in the bed nucleus of the stria terminalis induces food intake reduction and anxiety-like behaviors. Naka T, Ide S, Nakako T, Hirata M, Majima Y, Deyama S, Takeda H, Yoshioka M, Minami M. Neuropharmacology 67 326-330 2013
- Activation of the NMDA-receptor-neuronal nitric oxide synthase pathway within the ventral bed nucleus of the stria terminalis mediates the negative affective component of pain. Deyama S, Sugano Y, Mori S, Amano T, Yoshioka M, Kaneda K, Minami M. Neuropharmacology 118 59-68 2017/05
Conference Presentations
Others
- Benefits of research abroad Satoshi Deyama Nihon Yakurigaku Zasshi 149 3 139 2017/03/01
Arts and Fieldwork
Patent
Theme to the desired joint research
Grant-in-Aid for Scientific Research
○「抑うつ状態からの自発的治癒を担う神経回路機構とその破綻によるうつ病発症機構の解明」(2023-2025)
○「治療抵抗性うつ病に対するレゾルビン類経鼻投与の治療効果とその作用機序の解明」(2019-2021)
○ Grant-in-Aid for Young Scientists (B)「Involvement of neuroinflammation in the negative affective component of chronic pain: Effect of resolvin D1, an anti-inflammatory lipid mediator」(2013-2014)
Competitive research funding,Contribution
Collaborative research,Consignment study
Classes (Bachelors)
○Presentation and Debate(2023)
○Chemical Pharmacology 2(2023)
○Chemical Pharmacology 2(2023)
○Pharmacology 2(2023)
○Pharmacology 2(2023)
○Chemical Pharmacology 1(2023)
○Pharmacology 1(2023)
○Basic Medical and Pharmaceutical Sciences Rotation Practice（Course in Pharmaceutical Sciences）Ⅵ(2023)
○Experiments in Biology 2(2023)
○Experiments in Biology 2(2023)
○Introduction to Data Science(2023)
○Basic Physiology(2023)
○Basic Physiology(2023)
○Introduction to Data Science(2022)
○Basic Medical and Pharmaceutical Sciences Rotation Practice（Course in Pharmaceutical Sciences）Ⅵ(2022)
○Chemical Pharmacology 2(2022)
○Chemical Pharmacology 1(2022)
○Experiments in Biology 2(2022)
○Pharmacology 2(2022)
○Pharmacology 1(2022)
○Experiments in Biology 2(2022)
○Pharmacology 2(2022)
○Experiments in Biology 2(2022)
○Pharmacology 1(2022)
○Basic Physiology(2022)
○Basic Physiology(2022)
○Introduction to Data Science(2021)
○Pharmacology 2(2021)
○Pharmacology 1(2021)
○Experiments in Biology 2(2021)
○Basic Physiology(2021)
○Basic Physiology(2021)
○Experiments in Biology 2(2020)
○Pharmacology 2(2020)
○Pharmacology 1(2020)
○Basic Physiology(2020)
○Freshman Seminar I(2020)
○Experiments in Biology 2(2019)
○Basic Physiology(2019)
○Pharmacology 2(2019)
○Pharmacology 1(2019)
○Presentation and Debate (Freshman Seminar II)(2018)
○Pharmacology 2(2018)
○Pharmacology 1(2018)
○Experiments in Fundamental Chemistry(2018)
○Laboratory Rotation 2(2018)
○Pharmacology 2(2017)
○Pharmacology 1(2017)
○Pharmacology 2(2016)
Classes (Graduate Schools)
○Psychopharmacology(2023)
○Psychopharmacology(2023)
○Laboratory Rotation Ｉ(2023)
○Laboratory RotationⅡ(2023)
○Laboratory RotationⅠ(2023)
○Experimental Techniques in Precision Medicine Research(2023)
○Laboratory RotationⅠ(2023)
○Laboratory Rotation I(2023)
○Laboratory Rotation I(2023)
○Experimental Techniques in Precision Medicine Research(2022)
○Advanced Course of Pharmacological Studies for Drug Development(2022)
○Advanced Course of Pharmacological Studies for Drug Development(2021)
○Experimental Techniques in Precision Medicine Research(2021)
○Psychopharmacology(2021)
○Advanced Course of Pharmacological Studies for Drug Development(2020)
○Molecular Pharmacology(2016)